Fed. Circ. OKs PTAB Save Of Patent Covering Pfizer’s Toviaz
Law360 (January 11, 2019, 6:15 PM EST) -- The Federal Circuit ruled Friday that a patent on Pfizer Inc.’s incontinence drug Toviaz was correctly upheld in an inter partes review challenge from generics maker Amerigen Pharmaceuticals Ltd., while rejecting the patentee’s claim that Amerigen lacked standing to appeal.
The appeals court found that the Patent Trial and Appeal Board was correct to find in favor of UCB Pharma GmbH, which licenses the patent to Pfizer, and hold that Amerigen had not shown that the patent is invalid as obvious.
“We conclude that Amerigen's factual challenges to the board's decision are without merit and that substantial evidence supports the board’s...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!